The newer opioid agonist treatment with lower substitutive opiate doses is associated with better toxicology outcome than the older harm reduction treatment by Bizzarri, Jacopo V. et al.
Bizzarri et al. Ann Gen Psychiatry  (2016) 15:34 
DOI 10.1186/s12991-016-0109-z
PRIMARY RESEARCH
The newer Opioid Agonist Treatment 
with lower substitutive opiate doses is 
associated with better toxicology outcome 
than the older Harm Reduction Treatment
Jacopo V. Bizzarri1, Valentina Casetti1, Livia Sanna1, Angelo Giovanni Icro Maremmani2,3, Luca Rovai2, 
Silvia Bacciardi2, Daria Piacentino1, Andreas Conca1 and Icro Maremmani2,3,4*
Abstract 
Background: Charge-free heroin use disorder treatment in Italy follows two main approaches, i.e., harm reduction 
treatment (HRT) strategy in community low-threshold facilities for drug addiction and opioid agonist treatment (OAT) 
in high-threshold facilities for opioid addiction, focusing on pharmacological maintenance according to the Dole 
and Nyswander strategy. We aimed to compare the impact of HRT and OAT on patient outcome, as assessed through 
negativity for drugs on about 1-year urinalyses.
Methods: We examined retrospectively the urinalyses of HRT and OAT patients for which at least four randomly 
sampled urinalyses per month were available for about 1 year, during which patients were undergoing methadone or 
buprenorphine maintenance; urinalyses focused on heroin, cocaine, cannabinoids, and their metabolites.
Results: Included were 189 HRT and 58 OAT patients. The latter were observed for a significantly longer period. There 
was a higher proportion of heroin- and cocaine-clean urinalyses in OAT patients, with cocaine-clean urinalyses dis-
criminating best between the two groups. OAT patients were older, with longer dependence duration, more severe 
addiction history, and received lower methadone doses. Buprenorphine maintenance was more often associated with 
heroin-clean urinalyses. The higher the methadone doses, the lower were the percentage of heroin-clean urinalyses in 
HRT patients (negative correlation).
Conclusions: The OAT approach was related to higher recovery and polyabuse abstinence rates compared to the 
HRT approach, despite greater severity of substance use, psychiatric and physical comorbidities. Our results are 
consistent with the possibility to use lower maintenance opiate doses (after induction and stabilization in methadone 
treatment according to Dole and Nyswander methodology) in treating heroin addiction. This seemed to be impos-
sible adopting the currently accepted HRT model.
Keywords: Harm reduction treatment, Agonist opioid treatment, Urinalyses, Polysubstance use, Heroin, 
Cannabinoids, Cocaine
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Background
Opioid misuse is a long-term and often chronic con-
dition [1] that has an estimated prevalence of 0.40 % in 
the whole world, 0.82  % in Europe, and 0.43 in Italy [2, 
3]. It is associated with severe consequences for both 
individuals and society [4]. Heroin use is associated with 
somatic complications, including hepatitis B, hepatitis C, 
and immunodeficiency virus (HIV) infections, as well as 
pulmonary and cardiovascular complications [5], result-
ing in an increased risk of mortality [6]. Individuals with 
opioid use disorder also have a higher prevalence of psy-
chiatric disorders, particularly depression, anxiety, and 
personality disorders [7]. Moreover, opioid use disorder 
results in an economic burden for society, in terms of 
medical expenses, social welfare, loss of productivity, and 
costs of criminal activities [8].
The main pharmacological approach in treating opioid 
dependence involves opioid agonist maintenance [4, 9]. 
It consists in the replacement of the illegal drug, which 
has a 2- to 3-h half-life, with a prescribed opioid, which 
has a longer half-life and a good μ-receptor activity [10]. 
This approach aims to give relief from drug craving and 
withdrawal symptoms without providing patients with 
an intense high [9, 10]. The medications most frequently 
used are methadone and buprenorphine [9], which have 
proven to be effective in reducing heroin use, maintaining 
prolonged periods of abstinence, increasing retention in 
drug treatment, and reducing the risk of overdose-related 
death [4, 11, 12]. Given their proven efficacy, these two 
drugs have been included by the World Health Organiza-
tion in the Model List of Essential Medicines [4].
Charge-free heroin use disorder treatment in Italy 
follows two main approaches, i.e., harm reduction 
treatment (HRT) strategy [13, 14] in community low-
threshold facilities for drug addiction and opioid agonist 
treatment (OAT) in high-threshold facilities for opioid 
addiction, focusing on pharmacological maintenance 
according to the Dole and Nyswander strategy [9, 15–17]. 
Traditionally, physicians consider complete abstinence as 
the best and only treatment for substance use. However, 
in recent years this paradigm has been losing ground. 
The alternative treatment called HRT has been gaining 
stronger empirical support and wider practice, even if, as 
all evidence-based approaches [18], it is in need of fur-
ther development. The rationale of HRT is that patients 
will continue to use illicit drugs to some degree, as in 
some of them it is just unavoidable, and rather than push-
ing them into an abstinence they will not immediately 
or fully accept, physicians will step into provide support 
that can make drug use less harmful. It has been demon-
strated that methadone-based HRT, in which the use of 
illicit drugs is tolerated, is strongly related to decreased 
mortality from natural causes and from overdoses [19]. 
In HRT, doses and treatment duration are usually limited, 
regardless of clinical indication [20, 21], suggesting the 
possible usefulness of increasing them [22–25]. Patients 
are allowed to negotiate dosage lowering, regardless of 
urinalyses results, and to have their medication tapered 
earlier than advisable on the basis of the scientific litera-
ture. A weakness of HRT is that physicians do not seem 
eager to work with patients who continue to use drugs, 
even if in a safer or more controlled manner, but with-
out achieving a long-term withdrawal. A study carried 
out in Canada [26] found that only 56  % of physicians 
working in addiction treatment facilities would be will-
ing to provide long-term replacement therapy. OAT 
with methadone or buprenorphine has long been estab-
lished as the gold standard in treating opioid use disor-
ders, although not without fairly substantial financial 
and personal costs for patients taking part in this treat-
ment [27]. OAT has been shown to reduce the effects 
of opioid withdrawal and cravings, increase retention 
in treatment, and reduce risk behaviors that lead to the 
transmission of HIV and viral hepatitis [28–31]. How-
ever, abstinence as a medium- and long-term goal is not 
always achieved and some patients continue to abuse 
heroin during treatment [32]. Moreover, they frequently 
abuse other non-opiate drugs, such as cocaine and can-
nabinoids [8, 33]. Concurrent cocaine use is particularly 
challenging in clinical practice, as it is associated with 
poor prognosis both in terms of treatment drop-out and 
heavy concurrent use of heroin [33–37]. There is also an 
ongoing debate regarding the qualitative characteristics 
that define the optimal OAT intervention, namely the 
treatment threshold. “Treatment thresholds” are defined 
as barriers patients may face prior to and during treat-
ment. There are increasing numbers of studies suggest-
ing better treatment outcomes in low-threshold designs 
compared to high-threshold ones, due to accessibility so 
as to avoid waiting lists, use of personalized treatment 
options regarding medication choice and dose titration, 
and a treatment design that focuses on maintenance with 
emphasis on the retention of low-adherence patients 
[38]. In OAT four phases are envisaged [4, 9]: during the 
induction phase street heroin or other opioid drugs are 
substituted with an opioid agonist. During the stabiliza-
tion phase physicians determine the appropriate agonist 
dose for long-term maintenance. The doses are gradually 
increased, reflecting the results of urinalyses, until they 
produce opioid blockade and patients become tolerant to 
street heroin. Once this requirement is fulfilled, patients 
are defined as “stabilized” and the dose at which this goal 
has been accomplished is referred to as the “stabiliza-
tion dose”. No upper limit for doses exists. However, a 
time limit exists: patients who cannot achieve stabiliza-
tion within 1 year are transferred to the HRT approach. 
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Patients are not allowed to raise or lower doses by them-
selves. Take-home doses, without limitations and for 
maximum a week, are allowed once full compliance with 
the rules of the program is reached. This is the mainte-
nance phase. During the medically supervised withdrawal 
phase a slow reduction of the agonist dose is applied until 
patients are completely drug-free. Psychosocial support 
is usually provided [9], as it has been demonstrated that 
the association of pharmacotherapy and psychosocial 
interventions improves results at follow-up [13, 39].
Due to uncertainty regarding which treatment is more 
effective in the medium and long term, our aim was to 
compare the impact of HRT and OAT on patient out-
come, as assessed through negativity for drugs on about 
1-year regularly performed urinalyses. We hypothesized 
that OAT patients would show better outcomes in terms 
of heroin, cocaine, and cannabinoids use than HRT ones 
during maintenance and supervised withdrawal phases. 
We did not expect to find a relationship between this 
better outcome and the agonist opioid dose taken by 
patients.
Methods
Design of the study
We conducted a retrospective and naturalistic study to 
compare urinalyses results of HRT and OAT patients 
for which at least four randomly sampled urinalyses per 
month were available for about 1  year, during which 
patients were undergoing methadone or buprenorphine 
maintenance; urinalyses focused on heroin, cocaine, 
cannabinoids, and their metabolites. OAT patients were 
monitored after having completed their induction and 
stabilization phase. Given that maintenance phase in 
OAT patients did not generally start before 6  months 
of treatment, monitoring of HRT patients did not start 
before 6 months of treatment.
Sample
We took into account a dataset of more than 1000 her-
oin-dependent patients, who had requested treatment 
during the period 1994–2015 at the Dual Diagnosis Unit 
of Santa Chiara University Hospital in Pisa, Italy, and at 
the Drug Addiction Service of Bolzano, Italy. All patients 
received a diagnosis of opioid dependence with physical 
dependence according to DSM III/III-R/IV/IV-R/5 cri-
teria and gave their informed consent to the anonymous 
use of their clinical data for non-profit research.
Patients were selected if urinalyses for heroin, cocaine, 
and cannabinoids had been monitored for almost a year 
and collected randomly at least four times per month. 
As a result, 247 patients were included in the study: 189 
HRT patients and 58 OAT patients.
Instruments
Information regarding patients’ addiction history was 
obtained from the drug addiction history questionnaire 
(DAH-Q) [40]. As for toxicological urinalyses, urine 
specimens were tested for opioids, cocaine, cannabi-
noids, and their metabolites.
Drug addiction history questionnaire (DAH‑Q)
The DAH-Q [40] is a multi-dimensional question-
naire that gathers addiction-related information and 
is administered by a psychiatrist. It comprises the fol-
lowing eight areas: (1) demographic data; (2) physical 
health (hepatic, vascular, and lymphatic pathology, gas-
trointestinal disorders, sexual disorders, dental pathol-
ogy, HIV seropositivity); (3) mental health (awareness 
of illness, memory disorders, mood disorders, anxiety 
disorders, thought disorders, sensory perception dis-
orders); (4) social adjustment and environmental fac-
tors (employment, family, sex, socialization and leisure 
time, legal problems); (5) substance use (alcohol, opi-
ates, CNS depressants, CNS stimulants, hallucinogens, 
phencyclidine, cannabis, inhalants, polysubstance use); 
(6) substance use modalities (heroin intake, modality 
of use, stages of illness, nosography); (7) treatment his-
tory (previous and current treatments); (8) addiction 
history (age at first contact, age at onset of continuous 
use, dependence length, age at first treatment). Ten 
items are set up so as to elicit dichotomous answers 
(yes/no): (1) somatic comorbidities; (2) abnormal men-
tal status; (3) work problems; (4) household problems; 
(5) sexual problems; (6) socialization and leisure time 
problems; (7) drug-related legal problems; (8) poly-
substance abuse; (9) previous treatment; (10) combined 
treatments.
In the questionnaire, the modality of use is encoded 
according to Lahmeyer’s classification [41] as follows: 
(1) stables; (2) junkies; (3) two worlders; (4) loners. “Sta-
bles” are opioid addicts who have adopted conventional 
values, hold legitimate jobs, are generally law-abiding, 
and do not associate with other addicts. “Junkies” are 
closely identified with an addict subculture, are not legiti-
mately employed, and subsist on the proceeds of criminal 
activities. “Two worlders” engage in criminal activities 
and associate with other addicts, but are legitimately 
employed. “Loners” are not involved neither in the addict 
subculture, nor the conventional culture: they are usually 
unemployed and live on welfare benefits, rather than on 
the proceeds of criminal activities.
The questionnaire does not provide statistic or psycho-
metric indexes that require reliability or validity testing; it 
serves only as standardized medical record that we use in 
the routinely clinical practice.
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Toxicological urine analyses
Urine samples for toxicological analyses were randomly 
collected monthly to allow the evaluation of the presence 
of opiates, cocaine, cannabinoids, and their metabolites. 
The enzyme-multiplied immune technique was used for 
this purpose.
Data analysis
We compared HRT and OAT patients for socio-demo-
graphic data, addiction history, urinalyses, and opioid 
medication doses. The variables that differed significantly 
between the two groups were included in separate logis-
tic forward regression analyses, considering as a depend-
ent variable whether one belonged to the OAT group or 
not. Statistical significance was set at p < 0.05. All p val-
ues were two-sided. Statistical analyses were carried out 
using the SPSS package 20.0.
Results
Socio‑demographic features
In our study, 191 (77.3  %) patients were males and 56 
(22.7  %) females. Patients’ mean age  ±  standard devia-
tion (SD) was 33.64 ± 9.1 years (age range 16–59 years). 
Education length was less than 8  years in 169 (69.0  %) 
patients; 172 (70.8  %) patients were single; 85 (34.4  %) 
patients were unemployed. Economic condition was ade-
quate in 205 (83.0 %) patients, whereas 23 (9.3 %) received 
welfare benefit. Forty-eight (19.4 %) patients lived alone.
Table 1 shows the main socio-demographic differences 
between HRT and OAT patients.
Clinical features
OAT patients, more frequently than HRT ones, were 
affected by psychiatric and physical comorbidities and 
had been previously treated (Table 1). Their observation 
period was longer (Table 1). As regards addiction history, 
OAT patients showed a longer dependence duration than 
HRT ones. No difference was observed in terms of age of 
first heroin use, of continuous use, and of first treatment, 
as well as in terms of modalities of heroin use (Table 1).
Urinalyses
Table  2 shows the mean and SD of clean urinalyses of 
HRT and OAT patients according to the substitution 
medication type. At the multivariate level, there was a 
statistically significant interaction between the effects 
of clean urinalyses and treatment modality (p = 0.002). 
Differently, the interaction between the effects of clean 
urinalyses and substitution medication type was not sta-
tistically significant (p = 0.118). The interaction between 
treatment modality and substitution medication type 
was not statistically significant (p = 0.512) (Table 2). Dif-
ferences at the univariate level are reported in Table 2.
Table  3 shows that cocaine-clean urinalyses was the 
most discriminating characteristic of OAT patients (OR 
7.47E+21).
Substitution medication
The mean methadone dose was lower in OAT than in 
HRT patients. No differences in buprenorphine doses 
were observed.
Correlations between clean urinalyses and substitution 
medication doses
Regarding HRT patients, significant correlations were 
found between methadone dose and heroin-clean urinal-
yses (p = 0.017). High dosages correlated with a low per-
centage of heroin-clean urinalyses. A high percentage of 
heroin-clean urines correlated with a high percentage of 
cocaine- (p = 0.000) and cannabinoids- (p = 0.000) clean 
urinalyses. Considering OAT patients, no significant cor-
relations were found between methadone or buprenor-
phine dose and clean urinalyses. A high percentage of 
heroin-clean urines correlated with a high percentage of 
cocaine-clean (p = 0.009) urinalyses.
Discussion
Compared to HRT patients, OAT ones were older, more 
frequently females, more likely to live alone, and to have 
more workplace and justice issues. They had longer 
dependence duration, more severe addiction history, 
and received lower methadone doses. They were also 
observed for a significantly longer period. There was a 
higher proportion of heroin- and cocaine-clean urinaly-
ses in OAT patients, with cocaine-clean urinalyses dis-
criminating best between the two groups. Buprenorphine 
maintenance was more often associated with heroin-
clean urinalyses. The higher the methadone doses, the 
lower were the percentage of heroin-clean urinalyses in 
HRT patients (negative correlation).
Our results are inconsistent with those of the Cochrane 
review by Faggiano et  al. [23] that found that higher 
methadone doses (60–100  mg/day) were more effective 
than lower ones (1–39  mg/day) in reducing heroin use 
during methadone maintenance treatment. However, in 
line with our findings, several studies [10, 42, 43] failed 
to demonstrate a clear association between high metha-
done doses on the one hand and reduction of heroin use 
or clinical stabilization on the other hand. More specifi-
cally, Blaney and Craig [42] found no significant differ-
ences regarding any outcome variable (illicit drug use, 
treatment retention, missed medication days) by metha-
done dose and concluded that researchers should pay 
more attention to the interpersonal aspects of metha-
done maintenance treatment. Moreover, Reimer et  al. 
[10], using the opiate dosage adequacy scale (ODAS) in 
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a sample of patients in opioid replacement treatment, 
found that as many as 40.6 % suffered from an inadequate 
dosage, while 59.4 % had an adequate dosage. The “inad-
equate” group tended to receive higher doses of metha-
done when compared to the “adequate” group (70.6 
vs. 57.8  mg). Trafton et  al. [43] suggest that clinicians 
should individualize methadone doses as long as out-
comes are satisfactory: extremely low doses (2  mg/day) 
may be effective in some patients, while extremely high 
doses (over 160  mg/day) are required in other patients 
to reduce or stop heroin use. Furthermore, in our HRT 
patients we found a positive correlation between meth-
adone doses and the percentage of urines positive for 
heroin metabolites. We can hypothesize that the patients 
who received the highest methadone doses in clinical 
practice were those with a severe addiction, thus more 
difficult to treat. On the other hand, no significant corre-
lation was found between methadone dosage and heroin 
use among OAT patients.
In our sample, about 10  % of urine toxicology tests 
were positive for cocaine, with significant differences 
between HRT and OAT patients. Similarly, other studies 
Table 1 Demographic and clinical differences between harm reduction treatment and opioid agonist treatment patients
HRT strategy
N = 189
OAT strategy
N = 58
T/chi p
Demographics
 Age, M ± sd 30.41 ± 6.3 44.14 ± 8.7 −11.09 0.000
 Gender (females), N (%) 33 (17.5) 23 (39.7) 12.47 0.000
 Education (low), N (%) 120 (63.5) 49 (87.5) 11.63 0.001
 Single, N (%) 131 (70.1) 41 (73.2) 0.20 0.648
 Unemployed, N (%) 66 (35.1) 19 (32.8) 4.77 0.189
 Income (adequate), N (%) 151 (79.9) 54 (93.1) 5.48 0.019
 Welfare benefit, N (%) 3 (1.6) 20 (34.5) 56.87 0.000
 Living alone, N (%) 19 (10.1) 29 (50.0) 45.23 0.000
Clinical features at treatment entry
 Age heroin first use, M ± sd 18.64 ± 4.1 19.69 ± 5.1 −1.59 0.112
 Age of continuous use, M ± sd 21.33 ± 4.5 23.02 ± 6.0 −1.96 0.053
 Dependence length (years), M ± sd 7.30 ± 5.7 22.00 ± 9.1 −11.60 0.000
 Age first treatment, M ± sd 24.72 ± 4.9 25.36 ± 6.3 −0.75 0.477
 Somatic complications, presence, N (%) 130 (68.8) 51 (89.5) 9.64 0.002
 Altered mental status, presence, N (%) 139 (73.5) 55 (98.2) 15.95 0.000
 Job concerns, presence, N (%) 77 (41.6) 35 (66.0) 9.85 0.002
 Household concerns, presence, N (%) 57 (30.5) 33 (57.9) 14.10 0.000
 Loving concerns, presence, N (%) 64 (33.9) 38 (66.7) 19.41 0.000
 Social-leisure concerns, presence, N (%) 74 (39.2) 33 (57.9) 6.25 0.012
 Legal problems, presence, N (%) 56 (29.6) 36 (62.1) 19.98 0.000
 Polyabuse, presence, N (%) 77 (40.7) 16 (28.6) 2.71 0.099
 Past treated, N (%) 161 (85.2) 58 (100.0) 9.52 0.002
 Combined treatments, N (%) 164 (86.8) 54 (94.7) 2.75 0.097
 Heroin intake, daily or more, N (%) 113 (59.8) 41 (70.7) 2.24 0.134
 Modality of use, unstable, N (%) 58 (30.7) 16 (28.1) 0.14 0.706
 Periodic self detoxifications, N (%) 137 (72.5) 49 (84.5) 3.43 0.064
 Stage 3 reached, N (%) 147 (77.8) 46 (79.3) 0.06 0.805
 Dual diagnosis, presence, N (%) 108 (57.1) 32 (55.2) 0.07 0.791
 Observational period (months), M ± sd 13.34 ± 3.0 18.68 ± 3.8 −9.69 0.000
Substitution medications HRT strategy OAT strategy z* p
N = 102 N = 43
Methadone dose, M ± sd 67.21 ± 25.8 53.12 ± 25.9 −2.65 0.008
N = 87 N = 15
Buprenorphine dose, M ± sd 7.29 ± 4.2 6.47 ± 4.4 −0.94 0.343
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monitoring patients in opiate agonist treatment found 
cocaine-positive urines with toxicological values ranging 
between 4.3 and 13 % [10, 44].
Even though previous studies (Cochrane review, [23]) 
indicated that higher doses of methadone (60–100  mg/
day) were more effective to reduce cocaine use in patients 
in opiate agonist treatment, we found no association 
between cocaine use and methadone dosage in both 
groups of patients.
Our findings are consistent with those of Epstein et al. 
[44], who compared patients randomly assigned to meth-
adone doses of 70 and 100  mg/day, respectively. They 
found that the percentage of urines negative for cocaine 
or for opiates and cocaine simultaneously did not differ 
by dose. Noteworthy, Baumeister et  al. [45] found that 
patients in the low dose group had significantly fewer 
cocaine consumption days than patients in the currently 
recommended dose range >60 mg/day. Moreover, in line 
with previous studies [45–47], we found a positive asso-
ciation between heroin and cocaine use in HRT and OAT 
patients. Our findings suggest that methadone mainte-
nance has an important role in restraining most of the 
cases of pre-existing concurrent cocaine abuse. The onset 
of cocaine abuse during a successful methadone mainte-
nance program is quite unlikely and is best predicted by 
former analogous abuse [48]. Finally, we found neither 
a significant difference in buprenorphine doses among 
OAT and HRT patients nor any significant associations 
between doses of buprenorphine and heroin or cocaine 
use in both groups of patients. Buprenorphine seemed to 
confirm its role in clearing heroin urinalyses better than 
methadone [49].
Regarding the percentage of cannabis use, no sig-
nificant differences were found between HRT and OAT 
patients. Similarly to Epstein and Preston [50] we found 
that cannabis use was not associated with cocaine or her-
oin use.
In our opinion, it is of clinical interest that OAT 
patients, following a correct induction and once the 
Table 2 Clean urinalyses percentage of harm reduction and agonist opioid treatment patients according to substitution 
medication used
Multivariate test: modality effect: F = 5.24; df = 3; p = 0.002. Medication effect: F = 1.97; df = 3; p = 0.118. Modality*medication effect: F = 0.77; df = 3; p = 0.512
Modality Medication Clean urinalyses
Heroin Cocaine Cannabinoid
HRT Buprenorphine (N = 87) 0.88 ± 0.2 0.91 ± 0.2 0.75 ± 0.3
Methadone (N = 102) 0.79 ± 0.3 0.86 ± 0.2 0.68 ± 0.3
Total (N = 189) 0.83 ± 0.2 0.88 ± 0.2 0.71 ± 0.3
OAT Buprenorphine (N = 15) 0.97 ± 0.1 0.97 ± 0.1 0.83 ± 0.3
Methadone (N = 43) 0.93 ± 0.1 0.97 ± 0.1 0.70 ± 0.4
Total (N = 58) 0.94 ± 0.1 0.97 ± 0.1 0.73 ± 0.4
Total Buprenorphine (N = 102) 0.89 ± 0.2 0.92 ± 0.2 0.76 ± 0.3
Methadone (N = 145) 0.83 ± 0.2 0.89 ± 0.2 0.68 ± 0.3
Total (N = 247) 0.86 ± 0.2 0.90 ± 0.2 0.72 ± 0.3
Between‑subjects effects
Modality Heroin urinalyses F = 11.05; df = 1; p = 0.001
Cocaine urinalyses F = 11.09; df = 1; p = 0.001
Cannabinoid urinalyses F = 0.86; df = 1; p = 0.353
Medication Heroin urinalyses F = 3.98; df = 1; p = 0.047
Cocaine urinalyses F = 1.19; df = 1; p = 0.275
Cannabinoid urinalyses F = 3.73; df = 1; p = 0.055
Modality*medication Heroin urinalyses F = 0.68; df = 1; p = 0.409
Cocaine urinalyses F = 1.13; df = 1; p = 0.289
Cannabinoid urinalyses F = 0.37; df = 1; p = 0.542
Table 3 Most discriminant characteristics of OAT patients
Statistic: Chi square 99.33, df 3, p = 0.000 correct classified 90.8 %
Step Predictors B Odds ratio 95 % CI p
1 Dependence 
length
0.17 1.19 1.08–1.30 0.000
2 Duration of 
observation
0.38 1.46 1.17–1.82 0.001
3 Clean cocaine 
urinalyses
29.64 7.47E+12 46,674.13–
1.20E+21
0.002
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stabilization phase has taken place, can obtain lower per-
centages of heroin and cocaine in urinalyses compared 
to HRT patients, even if treated with significantly lower 
doses of methadone. In addition, lower use of cocaine 
during OAT is the most discriminating characteristics 
of this kind of treatment when compared to HRT strat-
egy. It must be underlined that, at treatment entry, OAT 
patients had a higher prevalence of physical and psychi-
atric comorbidities, a longer dependence history, greater 
work problems, more unsatisfactory households, and 
more legal problems than HRT patients.
Furthermore, our results support the hypothesis of 
Willembring et  al. [51] about the stability of the clinic’s 
patient population: “Clinics with low turnover and a 
large number of patients that were stabilized on metha-
done years ago are likely to have lower average doses 
while still maintaining high concordance with dosing 
recommendations”.
In a paper published in 1965 [52], Dole and Nyswan-
der observed that 22 heroin addicts had been stabilized 
by oral methadone. The medication seemed to have two 
useful effects: relief of narcotic hunger and induction 
of sufficient tolerance to block the euphoric effect of an 
average illegal dose of heroin. With this medication and 
a comprehensive program of rehabilitation the patients 
showed marked improvement, pointing to a good efficacy 
of the OAT strategy.
The limitations of this study are due to its retrospective 
design and to the small cohort of patients who underwent 
the assessment. A study designed specifically to elucidate 
this issue should be carried out. Assessments of the same 
patient in different clinical presentations of the natural 
history of heroin dependence would have provided more 
accurate information.
Conclusions
Even patients with more severe substance use disorder 
and with multiple psychiatric, physical and social comor-
bidities, when treated with an appropriate long-term 
opioid agonist treatment and a multi-modal approach, 
could have a significant recover and reach satisfactory 
outcomes in term of substance abstinence.
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